Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bart L Scott

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
Blood Advances|July 15, 2020
Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to wasteBart L Scott
Managed Care (Langhorne, Pa.)|January 21, 2010
Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomesBart L Scott
The American Journal of Medicine|March 21, 2002
Cases from the Osler Medical Service at Johns Hopkins UniversityBart L Scott
Hematology. American Society of Hematology. Education Program|December 4, 2020
Existing agents, novel agents, or transplantation for high-risk MDSBart L Scott
Blood|July 25, 2024
Change is not always goodBart L Scott
Clinical Advances in Hematology & Oncology : H&O|September 8, 2009
Clinical roundtable monograph. Combination therapies for MDSBart L Scott
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2018
It's Not All in the Conditioning or the Perils of Early Trial CessationBart L Scott
Oncology (Williston Park, N.Y.)|December 18, 2008
Management of myelodysplastic syndromes: 2008 updateBart L Scott, Eli Estey
Annual Review of Medicine|January 12, 2010
Myelodysplastic syndromesBart L Scott, H Joachim Deeg
Current Hematologic Malignancy Reports|October 16, 2012
Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditionsAaron T Gerds, Bart L Scott
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
Blood Advances|July 15, 2020
Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to wasteBart L Scott
Managed Care (Langhorne, Pa.)|January 21, 2010
Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomesBart L Scott
The American Journal of Medicine|March 21, 2002
Cases from the Osler Medical Service at Johns Hopkins UniversityBart L Scott
Hematology. American Society of Hematology. Education Program|December 4, 2020
Existing agents, novel agents, or transplantation for high-risk MDSBart L Scott
Blood|July 25, 2024
Change is not always goodBart L Scott
Clinical Advances in Hematology & Oncology : H&O|September 8, 2009
Clinical roundtable monograph. Combination therapies for MDSBart L Scott
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 21, 2018
It's Not All in the Conditioning or the Perils of Early Trial CessationBart L Scott
Oncology (Williston Park, N.Y.)|December 18, 2008
Management of myelodysplastic syndromes: 2008 updateBart L Scott, Eli Estey
Annual Review of Medicine|January 12, 2010
Myelodysplastic syndromesBart L Scott, H Joachim Deeg
Current Hematologic Malignancy Reports|October 16, 2012
Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditionsAaron T Gerds, Bart L Scott
Pageof 12